Effects of high-dose medroxyprogesterone treatment given for endometrial carcinoma on carbohydrate metabolism and liver function.
D000284:Administration, Oral; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism*; D003864:Depression, Chemical; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007273:Injections, Intramuscular; D007328:Insulin / Q000097:blood; D008099:Liver / Q000187:drug effects*; D008111:Liver Function Tests; D008525:Medroxyprogesterone / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D008875:Middle Aged; D013268:Stimulation, Chemical; D013997:Time Factors; D014594:Uterine Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology
D001786:Blood Glucose; D007328:Insulin; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D008525:Medroxyprogesterone; D001663:Bilirubin